Search result from the Trials Tracker
This trial has been archived
Few people with CF have normal blood glucose control and these glucose abnormalities eventually progress to cystic fibrosis-related diabetes (CFRD), the most common complication of CF. The combination of diabetes and CF leads to increased morbidity and a six-fold increase in mortality. People with CF are encouraged to consume a high calorie diet to maintain weight. This typically means eating food and drinks that are often high in fat and/or sugar. For people with CF who also need to control their blood glucose levels, high sugar intake can make this difficult. There is limited evidence to guide dietary therapy for...
- Trials Tracker ID
- TT001921
- Age range
- Between 11 and 30 years
- Length of participation
- 4 months
- Trial status
- Closed with results
- Therapeutic approach
- Nutritional-GI
Our Activity Unlimited programme aims to help everyone with cystic fibrosis (CF) take control of their health with sport, exercise and physiotherapy.
Search result from the Trials Tracker
This trial has been archived
Lung Clearance Index (LCI) measured by multiple breath washout (MBW) has been shown to be a sensitive and non-invasive method of detecting early airways disease in infants with cystic fibrosis (CF). An abnormal measurement at a young age has been shown to track into later life, and could identify children that require more aggressive treatment earlier on. Currently however there is a lack of multi-centre data and of suitable scalable methodologies that can be used outside of highly specialised settings. This is a multi-centre longitudinal observational study of this measurement, LCI, in children younger than 3 years with CF, with...
- Trials Tracker ID
- TT001916
- Age range
- Under 2 years
- Trial status
- Closed with results
- Therapeutic approach
- Other
Search result from the Trials Tracker
CF is caused by decreased quantity and/or function of the Cystic Fibrosis transmembrane conductance protein regulator (CFTR) protein due to mutations in the gene that codes for the CFTR protein. The CFTR protein regulates salt and water absorption and secretion and pH balance in sweat glands and multiple organs, including the lungs, pancreas, and other gastrointestinal organs. The most common disease-causing CFTR mutation is F508del and subjects can either have two copies of the gene, known as homozygous, or one copy, known as heterozygous. Therapies targeted at improving the function of the protein which is formed as a result of...
- Trials Tracker ID
- TT001906
- Age range
- 12 years and older
- Length of participation
- 24 weeks
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
This trial has been archived
To evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor (TEZ) and VX-561 (deuterated ivacaftor, also known as CTP-656) in subjects with cystic fibrosis (CF)who are homozygous for the F508del mutation (F/F)
These results suggest Kaftrio could be a more effective treatment than tezacaftor plus ivacaftor alone for people with cystic fibrosis with two copies of the F508del mutation.
- Trials Tracker ID
- TT001876
- Age range
- 12 years and older
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
This study is designed to evaluate the effectiveness and safety of lenabasum (JBT-101) in people with CF who have had pulmonary exacerbations. Lenabasum (JBT-101) is an oral medication that is aimed at reducing inflammation. It is thought to help the body increase production of anti-inflammatory molecules while reducing production of molecules that increase inflammation. Reduction of inflammation helps prevent permanent tissue damage in the lungs that happens when CF patients have pulmonary exacerbations. For study participants this study includes 6 months of study treatment with a 1 month follow up period. Study participants may remain on their current CF treatments
- Trials Tracker ID
- TT001871
- Age range
- 12 years and older
- Trial status
- Closed with results
- Therapeutic approach
- Anti-Inflammatory
Search result from the Trials Tracker
This trial has been archived
Cystic fibrosis affects the digestive system and leads to a number of unpleasant symptoms. Those relating to the bowels are often overlooked and can be hard to treat. We are hoping to evaluate a new questionnaire –the CF bowel score (CF-BS)–specifically designed to look at CF bowel disease. We hope it will improve identification and allow us to measure response to treatment. The patient will complete the CF-BS at their routine clinic appointment along with providing relevant clinical information. One group of patients will be sent home with the CF-BS to complete at home and return to us within a...
- Trials Tracker ID
- TT001866
- Age range
- 18 years and older
- Length of participation
- 1 week
- Trial status
- Closed with results
- Therapeutic approach
- Other
Search result from the Trials Tracker
This trial has been archived
A Phase 3, Randomised, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
- Trials Tracker ID
- TT001861
- Age range
- 12 years and older
- Length of participation
- 24 weeks
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
This trial has been archived
Gastro - oesophageal reflux disease(GORD) is a condition where acid from the stomach leaks out of the stomach and up into the oesophagus (gullet) It is common in patient with Cystic Fibrosis. Although symptoms such as heartburn and acid taste in the mouth can occur, often there are no symptoms. Studies have suggested a link between a worsening lung function and the amount of GORD. A potential mechanism is by the stomach content travelling into the lungs causing inflammation and altering the usual organisms that are present. If that is the case, there may be opportunities for new drugs and...
- Trials Tracker ID
- TT001856
- Age range
- 18+
- Length of participation
- 24 hours
- Trial status
- Closed with results
- Therapeutic approach
- Other
